Tenax Therapeutics, Inc.
$14.1
▼
-6.16%
2026-04-21 09:47:00
www.tenaxthera.com
NCM: TENX
Explore Tenax Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$247.99 M
Current Price
$14.1
52W High / Low
$18.38 / $4.63
Stock P/E
—
Book Value
$2.29
Dividend Yield
—
ROCE
-58.09%
ROE
-55.64%
Face Value
—
EPS
$-1.34
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
14
Beta
1.19
Debt / Equity
—
Current Ratio
14.56
Quick Ratio
14.56
Forward P/E
-9.87
Price / Sales
—
Enterprise Value
$628.02 M
EV / EBITDA
—
EV / Revenue
—
Rating
Strong Buy
Target Price
$29.57
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Dyne Therapeutics, Inc. | $20.02 | — | $3.37 B | — | -41.2% | -55.71% | $25 / $7.38 | $5.89 |
| 2. | Humacyte, Inc. | $0.69 | — | $157.68 M | — | -110.35% | 164.78% | $2.93 / $0.55 | $0.02 |
| 3. | LB Pharmaceuticals Inc | $31.67 | — | $875.16 M | — | -9.95% | -15.7% | $30.72 / $13.36 | $11.91 |
| 4. | Adaptive Biotechnologies Corporation | $14.58 | — | $2.23 B | — | -13.51% | -27.82% | $20.76 / $6.77 | $1.42 |
| 5. | Lisata Therapeutics, Inc. | $2.83 | — | $25.56 M | — | -124.1% | -75.53% | $5.07 / $1.81 | $1.68 |
| 6. | Kyverna Therapeutics, Inc. | $11.25 | — | $600.17 M | — | -65.99% | -64.67% | $13.67 / $1.78 | $3.85 |
| 7. | Connect Biopharma Holdings Limited | $2.68 | — | $158.82 M | — | -24.19% | -82.72% | $3.82 / $0.65 | $0.74 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -16.45 M | -16.81 M | -11.79 M | -11.34 M | -7.29 M | — |
| Net Profit | -15.54 M | -15.8 M | -10.85 M | -10.41 M | -6.27 M | — |
| EPS in Rs | -0.9 | -0.92 | -0.63 | -0.61 | -0.36 | -0.19 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -56.38 M | -19.49 M | -8.23 M | -11.05 M |
| Net Profit | -52.6 M | -17.6 M | -7.71 M | -11.05 M |
| EPS in Rs | -3.06 | -1.02 | -0.45 | -0.64 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 104.23 M | 96.69 M | 11.69 M | 3.4 M |
| Total Liabilities | 7.16 M | 4.69 M | 3.59 M | 1.91 M |
| Equity | 97.07 M | 91.99 M | 8.1 M | 1.49 M |
| Current Assets | 104.23 M | 96.69 M | 11.68 M | 3.21 M |
| Current Liabilities | 7.16 M | 4.69 M | 3.59 M | 1.85 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -35.8 M | -14.81 M | -5.9 M | -11.39 M |
| Investing CF | — | 0 M | 0 M | -0 M |
| Financing CF | 38.51 M | 99.87 M | 13.57 M | 7.93 M |
| Free CF | -35.8 M | -14.81 M | -5.9 M | -11.39 M |
| Capex | — | — | — | -0 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -128.27% | 30.2% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-01-03 | 1:0.0125 |
| 2023-01-05 | 1:0.05 |